{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T19:34:15Z","timestamp":1648755255037},"reference-count":56,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.2515\/therapie\/2013048","type":"journal-article","created":{"date-parts":[[2013,11,13]],"date-time":"2013-11-13T14:42:45Z","timestamp":1384353765000},"page":"303-312","source":"Crossref","is-referenced-by-count":1,"title":["Les m\u00e9dicaments g\u00e9n\u00e9riques et l\u2019\u00e9volution de la consommation des antihypertenseurs au Maroc"],"prefix":"10.1016","volume":"68","author":[{"given":"Ghizlane Berrada","family":"El Azizi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir","family":"Ahid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imane","family":"Ghannam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelmajid","family":"Belaiche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Hassar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yahia","family":"Cherrah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.2515\/therapie\/2013048_bb0200","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0828-282X(06)70275-6","article-title":"Worldwide epidemic of hypertension","volume":"22","author":"Chockalingam","year":"2006","journal-title":"Can J Cardiol"},{"key":"10.2515\/therapie\/2013048_bb0205","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"key":"10.2515\/therapie\/2013048_bb0210","series-title":"Global health risks: mortality and burden of disease attributable to selected major risks","author":"Mathers","year":"2009"},{"key":"10.2515\/therapie\/2013048_bb0215","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1097\/00004872-200305000-00013","article-title":"Prevalence of the main cardiovascular risk factors in Morocco: results of a national survey 2000","volume":"21","author":"Tazi","year":"2003","journal-title":"J Hypertens"},{"key":"10.2515\/therapie\/2013048_bb0220","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hpm.816","article-title":"An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom","volume":"20","author":"Mossialos","year":"2005","journal-title":"Int J Health Plann Manage"},{"key":"10.2515\/therapie\/2013048_bb0225","first-page":"45","article-title":"New safe medicines faster: a new concept for drug development","volume":"74","author":"Dirach","year":"2003","journal-title":"NSMF Workshop Report"},{"key":"10.2515\/therapie\/2013048_bb0230","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2307\/2556056","article-title":"Entry decisions in the generic pharmaceutical industry","volume":"30","author":"Morton","year":"1999","journal-title":"Rand J Econ"},{"key":"10.2515\/therapie\/2013048_bb0235","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1472-6963-8-50","article-title":"Influence of mandatory generic substitution on pharmaceutical sales patterns: a national study over five years","volume":"8","author":"Andersson","year":"2008","journal-title":"BMC Health Serv Res"},{"key":"10.2515\/therapie\/2013048_bb0240","doi-asserted-by":"crossref","first-page":"w832","DOI":"10.1377\/hlthaff.28.5.w832","article-title":"How medicare could get better prices on prescription drugs","volume":"28","author":"Outterson","year":"2009","journal-title":"Health Aff (Millwood)"},{"key":"10.2515\/therapie\/2013048_bb0245","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1001\/jama.2008.758","article-title":"Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis","volume":"300","author":"Kesselheim","year":"2008","journal-title":"JAMA"},{"key":"10.2515\/therapie\/2013048_bb0250","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0168-8510(00)00061-0","article-title":"A comparative analysis of generics markets in five European countries","volume":"51","author":"Garattini","year":"2000","journal-title":"Health Policy"},{"key":"10.2515\/therapie\/2013048_bb0255","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/17512433.1.4.497","article-title":"Trends in generic prescribing and dispensing in Europe","volume":"1","author":"Simoens","year":"2008","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.2515\/therapie\/2013048_bb0260","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2471\/BLT.06.033647","article-title":"The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries","volume":"85","author":"Mendis","year":"2007","journal-title":"Bull World Health Organ"},{"key":"10.2515\/therapie\/2013048_bb0265","series-title":"The world medicines situation","author":"World Health Organization","year":"2004"},{"key":"10.2515\/therapie\/2013048_bb0270","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2165\/11319570-000000000-00000","article-title":"Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data","volume":"10","author":"Boersma","year":"2010","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.2515\/therapie\/2013048_bb0275","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2147\/CEOR.S11933","article-title":"Antihypertensive therapy among newly treated patients: An analysis of adherence and cost of treatment over years","volume":"2","author":"Esposti","year":"2010","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.2515\/therapie\/2013048_bb0280","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/1472-6963-8-133","article-title":"Antihypertensive medication prescription patterns and time trends for newly-diagnosed uncomplicated hypertension patients in Taiwan","volume":"8","author":"Liu","year":"2008","journal-title":"BMC Health Serv Res"},{"issue":"23","key":"10.2515\/therapie\/2013048_bb0285","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1161\/CIRCULATIONAHA.105.535922","article-title":"Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level","volume":"112","author":"Gaziano","year":"2005","journal-title":"Circulation"},{"issue":"1","key":"10.2515\/therapie\/2013048_bb0290","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1478-7547-11-2","article-title":"Cost-utility analysis of antihypertensive medications in Nigeria: a decision analysis","volume":"11","author":"Ekwunife","year":"2013","journal-title":"Cost Eff Resour Alloc"},{"key":"10.2515\/therapie\/2013048_bb0295","series-title":"Report code: GBIHC053MR","article-title":"Antihypertensives market to 2016 - Generic erosion following patent expiry of major ARBS to impact the market. GBI Research (Global business intelligence)","year":"2010"},{"key":"10.2515\/therapie\/2013048_bb0300","article-title":"Recommandations de bonnes pratiques m\u00e9dicales, affection longue dur\u00e9e, l\u2019hypertension art\u00e9rielle de l\u2019adulte, CIM 10 : I10, code ANAM : E113","year":"2010","journal-title":"R\u00e9f ANAM"},{"key":"10.2515\/therapie\/2013048_bb0305","series-title":"Rapport final","first-page":"38","article-title":"\u00c9tude sur le financement des soins de sant\u00e9 au Maroc","author":"Organisation mondiale de la sant\u00e9","year":"2007"},{"key":"10.2515\/therapie\/2013048_bb0310","series-title":"Maroc, perspective \u00e9conomique en Afrique, \u00a9 BAfD\/OCDE","first-page":"471","year":"2008"},{"key":"10.2515\/therapie\/2013048_bb0315","unstructured":"D\u00e9cret n\u00b0 2\u201305-733 du 11 joumada II 1426 (18 juillet 2005) pris pour l\u2019application de la loi n\u00b0 65\u201300 portant code de la couverture m\u00e9dicale de base. http:\/\/www.assurancemaladie.ma\/upload\/document\/decret733.pdf."},{"key":"10.2515\/therapie\/2013048_bb0320","first-page":"46","author":"WHO collaborating centre for drug statistics methodology anatomical therapeutic chemical (ATC) classification index with defined daily doses (DDDs) 2011","year":"2010","journal-title":"Oslo"},{"key":"10.2515\/therapie\/2013048_bb0325","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2515\/therapie:2005077","article-title":"Methods for the measurement of drug consumption: application to antibiotics","volume":"60","author":"Sommet","year":"2005","journal-title":"Therapie"},{"key":"10.2515\/therapie\/2013048_bb0330","author":"WHO collaborating center for drug statistics methodology. Guidelines for ATC classification and DDD assignment"},{"key":"10.2515\/therapie\/2013048_bb0335","unstructured":"Haut commissariat au plan-Maroc (HCP). http:\/\/www.hcp.ma."},{"key":"10.2515\/therapie\/2013048_bb0340","unstructured":"Secr\u00e9tariat g\u00e9n\u00e9ral du gouvernement. Bulletin officiel N\u00b04084, 21 rejeb 1411 (6 f\u00e9vrier 1991): 39-ISSN: 0851-1217. Version fran\u00e7aise. http:\/\/www.sgg.gov.ma\/BO\/bulletin\/Fr\/1991\/BO_4084_fr.pdf"},{"key":"10.2515\/therapie\/2013048_bb0345","series-title":"Bulletin officiel N\u00b05654, 5 Chaabane 1429","author":"Secr\u00e9tariat g\u00e9n\u00e9ral du gouvernement","year":"2008"},{"issue":"10","key":"10.2515\/therapie\/2013048_bb0350","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/pds.3288","article-title":"Trends in antihypertensives use among Moroccan patients","volume":"21","author":"Berrada El Azizi","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.2515\/therapie\/2013048_bb0355","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1472-6963-5-21","article-title":"International variation in prescribing antihypertensive drugs: its extent and possible explanations","volume":"5","author":"Fretheim","year":"2005","journal-title":"BMC Health Serv Res"},{"key":"10.2515\/therapie\/2013048_bb0360","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.sapharm.2005.10.001","article-title":"Consumption and costs of antihypertensive drugs in Mexico: are diuretic agents a standing technological trajectory?","volume":"2","author":"Altagracia-Mart\u00ednez","year":"2006","journal-title":"Res Social Adm Pharm"},{"key":"10.2515\/therapie\/2013048_bb0365","series-title":"Agence Fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Afssaps) Analyse des ventes de m\u00e9dicaments aux officines et aux h\u00f4pitaux en France 1998 \u2013 2008","author":"Afssaps","year":"2010"},{"issue":"3","key":"10.2515\/therapie\/2013048_bb0370","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1365-3156.2009.02453.x","article-title":"Prices of antihypertensive medicines in sub-Saharan Africa and alignment to WHO\u2019s model list of essential medicines","volume":"15","author":"Twagirumukiza","year":"2010","journal-title":"Trop Med Int Health"},{"issue":"3","key":"10.2515\/therapie\/2013048_bb0375","first-page":"350","article-title":"Unaffordable drug prices: the major cause of non-compliance with hypertension medication in Ghana","volume":"7","author":"Ohene Buabeng","year":"2004","journal-title":"J Pharm Pharm Sci"},{"key":"10.2515\/therapie\/2013048_bb0380","series-title":"Caisse nationale de l\u2019Assurance Maladie \u00ab CNAM \u00bb","article-title":"Consommation et d\u00e9penses de m\u00e9dicaments en France et en Europe : \u00e9volutions 2006 \u2013 2009","year":"2011"},{"key":"10.2515\/therapie\/2013048_bb0385","series-title":"\u00c9valuation des m\u00e9dicaments antihypertenseurs et place dans la strat\u00e9gie th\u00e9rapeutique","author":"Haute autorit\u00e9 de sant\u00e9","year":"2010"},{"issue":"5","key":"10.2515\/therapie\/2013048_bb0390","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/00004872-200305000-00001","article-title":"European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement","volume":"21","author":"O\u2019Brien","year":"2003","journal-title":"J Hypertens"},{"issue":"21","key":"10.2515\/therapie\/2013048_bb0395","first-page":"2413","volume":"15","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.2515\/therapie\/2013048_bb0400","series-title":"Prise en charge des patients adultes atteints d\u2019hypertension art\u00e9rielle essentielle-Actualisation 2005","author":"Haute autorit\u00e9 de sant\u00e9","year":"2005"},{"key":"10.2515\/therapie\/2013048_bb0405","series-title":"Guide de poche pour l\u2019\u00e9valuation et la prise en charge du risque cardiovasculaire","article-title":"Pr\u00e9vention des maladies cardiovasculaires","author":"Organisation mondiale de sant\u00e9","year":"2007"},{"key":"10.2515\/therapie\/2013048_bb0410","unstructured":"Consommation et d\u00e9penses de m\u00e9dicaments : comparaison des pratiques fran\u00e7aises et europ\u00e9ennes. Caisse nationale de l\u2019Assurance Maladie \u00ab CNAM \u00bb \u2013Point d\u2019information mensuel 2007. http:\/\/www.ameli.fr\/fileadmin\/user_upload\/documents\/Consommation_et_depenses_de_medicaments_-_Europe.pdf"},{"key":"10.2515\/therapie\/2013048_bb0415","series-title":"Le m\u00e9dicament g\u00e9n\u00e9rique : le march\u00e9 mondial du m\u00e9dicament g\u00e9n\u00e9rique","author":"Dussol","year":"2009"},{"key":"10.2515\/therapie\/2013048_bb0420","first-page":"13","article-title":"Les m\u00e9dicaments g\u00e9n\u00e9riques : comment les pouvoirs publics cr\u00e9ent un march\u00e9 (1995-2010)","author":"Nouguez","year":"2010","journal-title":"Les notes de l\u2019Institut europ\u00e9en du Salariat"},{"key":"10.2515\/therapie\/2013048_bb0425","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1478-7547-3-2","article-title":"A cost-minimization analysis of diuretic-based antihypertensive therapy reducing cardiovascular events in older adults with isolated systolic hypertension","volume":"3","author":"Chen","year":"2005","journal-title":"Cost Eff Resour Alloc"},{"key":"10.2515\/therapie\/2013048_bb0430","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3917\/rfas.073.0025","article-title":"M\u00e9dicament et r\u00e9gulation en France","volume":"4","author":"Lancry","year":"2007","journal-title":"Revue Fran\u00e7aise des Affaires sociales"},{"key":"10.2515\/therapie\/2013048_bb0435","article-title":"\u00c9volution r\u00e9cente des grandes classes th\u00e9rapeutiques de m\u00e9dicaments","author":"Commission des comptes de la s\u00e9curit\u00e9 sociale","year":"2009","journal-title":"\u00c9clairages maladie"},{"key":"10.2515\/therapie\/2013048_bb0440","article-title":"Comparaisons europ\u00e9ennes sur la consommation de m\u00e9dicaments","author":"Commission des comptes de la s\u00e9curit\u00e9 sociale","year":"2007","journal-title":"\u00c9clairages maladie"},{"key":"10.2515\/therapie\/2013048_bb0445","unstructured":"Ayadi I. Impact de la r\u00e9forme de l\u2019assurance maladie en Tunisie sur l\u2019offre et la demande des m\u00e9dicaments. Th\u00e8se Universit\u00e9 Paris Dauphine 12\u20132009. http:\/\/basepub.dauphine.fr\/handle\/123456789\/7671."},{"key":"10.2515\/therapie\/2013048_bb0450","unstructured":"Tazi MA, Abir-Khalil S, Chaouki N, et al. Enqu\u00eate nationale sur les facteurs de risques des maladies cardiovasculaires-2000. Bulletin \u00e9pid\u00e9miologique 1er et 2e trimestre 2003. http:\/\/www.sante.gov.ma\/departements\/delm\/Bulletin\/Intranet%20BE%2053-54.pdf"},{"key":"10.2515\/therapie\/2013048_bb0455","doi-asserted-by":"crossref","first-page":"827","DOI":"10.26719\/2009.15.4.827","article-title":"Risk factors for hypertension among the adult Moroccan population","volume":"15","author":"Tazi","year":"2009","journal-title":"East Mediterr Health J"},{"key":"10.2515\/therapie\/2013048_bb0460","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1097\/00005650-199912000-00012","article-title":"An epidemiological approach to drug prescribing quality assessment: a study in primary care practice in France","volume":"37","author":"Coste","year":"1999","journal-title":"Med Care"},{"key":"10.2515\/therapie\/2013048_bb0465","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/bmj.311.7000.293","article-title":"Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs, a study of a United Kingdom population","volume":"311","author":"Jones","year":"1995","journal-title":"BMJ"},{"key":"10.2515\/therapie\/2013048_bb0470","first-page":"505","article-title":"Acceptance of generic prescribing in general practice: effect of patient education and reference prices","volume":"16","author":"Valles","year":"2002","journal-title":"Gac Sanit"},{"key":"10.2515\/therapie\/2013048_bb0475","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s002280000200","article-title":"Different versions of the anatomical therapeutic chemical classification system and the defined daily dose: are drug utilisation data comparable","volume":"56","author":"Ronning","year":"2000","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716309349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716309349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T21:47:22Z","timestamp":1596836842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716309349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0040595716309349"],"URL":"https:\/\/doi.org\/10.2515\/therapie\/2013048","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}